Poseida Therapeutics

$6.37 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.

Stock Analysis

last close $6.37
1-mo return -16.9%
3-mo return -29.2%
avg daily vol. 261.25T
52-week high 13.98
52-week low 6.2
market cap. $409M
forward pe -
annual div. -
roe -545.2%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 50.1%
baraka

Subscribe now for daily local and international financial news

Subscribe